- Home
- ADSE vs IOVA Comparison
ADSE vs IOVA Comparison
Compare ADSE & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADSE
- IOVA
- Stock Information
- Founded
- ADSE 1980
- IOVA 2007
- Country
- ADSE Ireland
- IOVA United States
- Employees
- ADSE N/A
- IOVA N/A
- Industry
- ADSE Industrial Specialties
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ADSE Consumer Discretionary
- IOVA Health Care
- Exchange
- ADSE Nasdaq
- IOVA Nasdaq
- Market Cap
- ADSE 713.5M
- IOVA 771.4M
- IPO Year
- ADSE N/A
- IOVA N/A
- Fundamental
- Price
- ADSE $13.80
- IOVA $1.71
- Analyst Decision
- ADSE
- IOVA Buy
- Analyst Count
- ADSE 0
- IOVA 10
- Target Price
- ADSE N/A
- IOVA $12.22
- AVG Volume (30 Days)
- ADSE 87.0K
- IOVA 11.8M
- Earning Date
- ADSE 05-12-2025
- IOVA 08-07-2025
- Dividend Yield
- ADSE N/A
- IOVA N/A
- EPS Growth
- ADSE N/A
- IOVA N/A
- EPS
- ADSE N/A
- IOVA N/A
- Revenue
- ADSE $113,896,884.00
- IOVA $212,679,000.00
- Revenue This Year
- ADSE $219.58
- IOVA $86.62
- Revenue Next Year
- ADSE N/A
- IOVA $69.95
- P/E Ratio
- ADSE N/A
- IOVA N/A
- Revenue Growth
- ADSE 2.45
- IOVA 11070.12
- 52 Week Low
- ADSE $9.00
- IOVA $1.64
- 52 Week High
- ADSE $16.35
- IOVA $12.51
- Technical
- Relative Strength Index (RSI)
- ADSE 65.86
- IOVA 36.89
- Support Level
- ADSE $12.45
- IOVA $1.95
- Resistance Level
- ADSE $13.60
- IOVA $2.47
- Average True Range (ATR)
- ADSE 0.88
- IOVA 0.16
- MACD
- ADSE 0.30
- IOVA -0.00
- Stochastic Oscillator
- ADSE 97.54
- IOVA 6.41
About ADSE ADS-TEC ENERGY PLC
ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services that enable the customer to control and manage the system. ADSE generates revenue mainly through the sale of its products, services, and Big-LinX. Geographically, it derives a majority of its revenue from Germany.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.